“Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.”
Website
Website
Location: Germany, Lower Saxony, Hanover
Employees: 11-50
Total raised: $167.11M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Fund+ | fundplus.b... |
| 25.08.2021 | Coparion | coparion.v... |
| 03.09.2021 | Hadean Ven... | hadeanvent... |
| 17.07.2021 | High-Tech ... | htgf.de |
| - | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 28.08.2021 | Series B | $75.49M | Hadean Ven... |
| 25.08.2021 | Series B | $75.33M | - |
| 11.05.2017 | - | $16.3M | - |
Mentions in press and media 15
| Date | Title | Description |
| 15.01.2026 | HTGF: Where public mandate meets venture discipline | While many venture capital funds are optimised for speed, scale, and short fund lifecycles, High-Tech Gründerfonds (HTGF) was built to address a structural gap in Germany’s innovation ecosystem. HTGF combines public mandate with private cap... |
| 09.04.2024 | Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease | Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional p... |
| 27.07.2022 | Cardior Announces First Patient Dosed in Phase 2 Study | Hanover, Germany, July 20, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their ... |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients • Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fu... |
| 31.08.2021 | Digital health news, funding roundup in the prior week; August 30 | Headspace's resilience brand and Ginger's clinical heft create mental health powerhouse Bambi Francisco Roizen sits down with Russ Glass, CEO of newly-formed Headspace Health, the combination of Ginger, a provider of on-demand coaching, the... |
| 26.08.2021 | Biopharma startup Cardior lands €64M Series B | Germany-based Cardior Pharmaceuticals has secured €64 million in a round led by Inkef Capital, with support from BioMedPartners, Hadean Ventures, LSP and others. The startup develops RNA-based therapeutics to prevent, repair and reverse hea... |
| 26.08.2021 | The CEO of one-time unicorn HeadSpin gets arrested for alleged fraud | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Meet the modern workforce From DXC Too much power in one founder can be a dangerous ... |
| 26.08.2021 | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease | Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinica... |
| 26.08.2021 | The CEO of one-time unicorn HeadSpin gets arrested for alleged fraud | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Could new tech make you look forward to airline travel? From NEC Too much power in o... |
| 25.08.2021 | Cardior Raises €64M in Series B Funding | Cardior Pharmaceuticals, a Hanover, Germany-based clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, closed a €64m ($76m) Series B financing round. The round was led by In... |
Show more